Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quadruple Oral Therapy (TZD vs SGLT-2i) in T2D
NCT04013581Phase 4Completed
- Sponsor
- Yonsei University
- Start
- Aug 2019
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of pioglitazone in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Yonsei University. Primary endpoint: Change of HbA1c at 24 weeks. Started Aug 2019; status: completed.
02
Drugs
pioglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04013581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04013581.